GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » AIM ImmunoTech Inc (LTS:0A4Y) » Definitions » Other Income (Expense)

AIM ImmunoTech (LTS:0A4Y) Other Income (Expense) : $-2.16 Mil (TTM As of Dec. 2024)


View and export this data going back to 2014. Start your Free Trial

What is AIM ImmunoTech Other Income (Expense)?

AIM ImmunoTech's other income expense for the AIM ImmunoTech's pretax income for the three months ended in Dec. 2024 was $-1.79 Mil. Its other income expense for the trailing twelve months (TTM) ended in Dec. 2024 was $-2.16 Mil.

AIM ImmunoTech Other Income (Expense) Historical Data

The historical data trend for AIM ImmunoTech's Other Income (Expense) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

AIM ImmunoTech Other Income (Expense) Chart

AIM ImmunoTech Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Other Income (Expense)
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.29 -2.00 -0.15 1.89 -2.16

AIM ImmunoTech Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Other Income (Expense) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.17 -0.09 -0.54 0.27 -1.79

AIM ImmunoTech Other Income (Expense) Calculation

Other income expense includes minority interest. Minority interest is a significant but non-controlling ownership of less than 50% of a company's voting shares by either an investor or another company.

Other Income (Expense) for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-2.16 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

AIM ImmunoTech  (LTS:0A4Y) Other Income (Expense) Explanation

Minority interest is reported on the consolidated income statement as a share of profit belonging to minority shareholders.

AIM ImmunoTech Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » AIM ImmunoTech Inc (LTS:0A4Y) » Definitions » Other Income (Expense)
Comparable Companies
KLTO CERO BZYR CELZ AZTR CPMV SILO KTTA IBO CMND VRTX ASX:CSL REGN XKRX:207940 XBRU:ARGX ALNY XBRU:UCB ONC BNTX XKRX:068270
Traded in Other Exchanges
AIMI:USA HXB2:Germany
Address
2117 SW Highway 484, Ocala, FL, USA, 34473
Website
https://www.aimimmuno.com
AIM ImmunoTech Inc is an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, viral diseases, and immune-deficiency disorders, and to treat cancers for which there are currently inadequate or unmet therapies. Its flagship products are Ampligen (rintatolimod) and Alferon N Injection (Interferon alfa). Ampligen is a double-stranded RNA (dsRNA) molecule being developed for globally important cancers, viral diseases, and disorders of the immune system. Ampligen is approved for commercial sale in the Argentine Republic for the treatment of severe Chronic Fatigue Syndrome (CFS).

AIM ImmunoTech Headlines

No Headlines